Cellective Therapeutics developed monoclonal antibody therapies targeting B-cell antigens CD19, CD20, and CD22, believed to play key roles in immune regulation. The company was acquired by MedImmune in an all-cash transaction to expand its pipeline for cancer and autoimmune disease treatments.
